Newsroom | 5143 results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed financial guidance for the year ending December 31, 2026. First Quarter 2026 Financial and Strategic Highlights Achieved record first quarter pump shipments, sales and gross margin: Shipments of more than 29,000 pumps worldwide, including 19,000 pumps in the United States Sales o...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opport...

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, an AI-powered health technology leader, today announced that it has been named winner of the “Best Overall Digital Health Company” award for the fourth consecutive year in the MedTech Breakthrough Awards. The annual awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market. This is...

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of diabetes management and glycemic safety across the care continuum, today announced it has been selected as the winner of the “Best Overall MedTech Software” award in the 10th annual MedTech Breakthrough Awards program. The recognition encompasses Glooko’s suite of software solutions, including the Glooko diabetes management platform, EndoTool® Glucose...

SEATTLE--(BUSINESS WIRE)--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and pickup within minutes through in-office kiosk locations soon, addressing a critical access gap for the more than 36 million Americans living with type 2 diabetes. Custo...

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (the "Company"), a world leader in blood glucose monitoring, today announced the appointment of Jonathan Salkin as Chief Executive Officer, effective immediately. Salkin will succeed Michael Hooks and James Rushing who have been serving as Co-Interim CEOs since January 2026. Hooks will continue to serve as Chairman of the Board and Rushing will continue in his roles as Executive Vice President and Chief Financial Officer. Salkin joins LifeScan with more t...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company’s guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4...

BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic R...

BREMA, Germania--(BUSINESS WIRE)--Kerecis, l'azienda pioniera nell'utilizzo della pelle di pesce intatta ottenuta in modo sostenibile nella terapia cellulare e nella rigenerazione dei tessuti, avrà un importante ruolo scientifico e pedagogico alla EWMA‑DEWU 2026 Conference, che si svolgerà il 6-8 maggio al Messe & Congress Centrum Bremen a Brema, Germania. Quest'anno, l'incontro della European Wound Management Association (EWMA) si terrà insieme al Deutscher Wundkongress (DEWU), unendo due...

BREMEN, Duitsland--(BUSINESS WIRE)--Kerecis, het bedrijf dat baanbrekend werk verricht op het gebied van het gebruik van duurzaam gewonnen intacte vissenhuid in celtherapie en weefselregeneratie, zal een prominente rol spelen op wetenschappelijk en educatief vlak tijdens de EWMA-DEWU 2026-conferentie, die van 6 tot en met 8 mei plaatsvindt in het Messe & Congress Centrum Bremen in Bremen, Duitsland Dit jaar wordt de bijeenkomst van de European Wound Management Association (EWMA) gezamenlijk...